Advertisement

Table of Contents

November 30, 2017; 130 (22)

INSIDE BLOOD COMMENTARIES

PERSPECTIVE

BLOOD SPOTLIGHT

REVIEW ARTICLES

CLINICAL TRIALS AND OBSERVATIONS

  • Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
    Philippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Elizabeth A. Punnoose, Jaclyn Cordero, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Kevin J. Freise, Joel D. Leverson, Sari Heitner Enschede, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo and Simon J. Harrison
  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
    Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, Thierry Facon, Martine Amiot, Philippe Moreau, Elizabeth A. Punnoose, Stefanie Alzate, Martin Dunbar, Tu Xu, Suresh K. Agarwal, Sari Heitner Enschede, Joel D. Leverson, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo and Cyrille Touzeau

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

LETTER TO BLOOD

BLOOD WORK

  • The unused iron
    Armin Rashidi and Scott Gilles